NCT03690362View on ClinicalTrials.gov

VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 6, 2018

Primary Completion Date

November 21, 2018

Study Completion Date

November 21, 2018

Conditions
Pharmacokinetics
Interventions
DRUG

VNRX-5133 and VNRX-5022

intravenous infusion

Trial Locations (2)

32809

Orlando Cliniical Research Associates, Orlando

37920

New Orleans Center for Clinical Research, Knoxville

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Venatorx Pharmaceuticals, Inc.

INDUSTRY

NCT03690362 - VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment | Biotech Hunter | Biotech Hunter